$21.87 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest



ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program.

Stock Analysis

last close $20.94
1-mo return -18.7%
3-mo return 19%
avg daily vol. 1.21M
52-week high 54.58
52-week low 15.68
market cap. $3.7B
forward pe -
annual div. -
roe -31.4%
ltg forecast -
dividend yield -
annual rev. $474M
inst own. 91.4%

Subscribe now for daily local and international financial news